Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2- early breast cancer undergoing chemo-endocrine therapy

Background: While existing multi-gene assays aid adjuvant treatment decisions, no gene signature has identified HR+/HER2- early breast cancer (EBC) patients at high recurrence risk post-chemo-endocrine therapy (C-ET). Methods: Clinical data and RNA sequencing information from 1457 HR+/HER2- breast c...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoyan Wu, Xunxi Lu, Wenchuan Zhang, Xiaorong Zhong, Hong Bu, Zhang Zhang
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Breast
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625005016
Tags: Add Tag
No Tags, Be the first to tag this record!